OptimizeRx Corporation (OPRX) earns a Roarable Rating of B- (Buy) with 71/100 RQD Confidence. High-quality cash engine (67.3% gross margin, 7% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
As of 2026-11-03, OptimizeRx Corporation (NASDAQ: OPRX) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 71/100 at a spot price of $9.41 (+0.97% 1D, market cap $175.6M). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 12/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 16/20, and Executive Insider Alignment 15/20. Across 1009 tracked Consumer Discretionary issuers, OPRX ranks #143 in composite RQD confidence.
Within the Consumer Discretionary sector (Business Services), OPRX carries a Roarable B- (71/100 RQD), trailing P/E of 34.4x, gross margin of 67.3%, and ROIC of 7.3%. By comparison, UXIN (Uxin Limited ADS) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $195.8M) and DHX (DHI Group Inc.) posts a D grade (51/100 RQD, P/E N/A, ROIC -7.4%, cap $196.3M). Among the 5-stock peer group, OPRX leads on earnings multiple (34.4x) while OPRX leads on capital efficiency (7.3% ROIC).
Per OPRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001448431), OptimizeRx Corporation generated $109.4M in revenue (+18.8% YoY), $5.1M in net income, and $18.7M in free cash flow against $176.9M in total assets and $21.4M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 29% of 52W Range • RSI-14 at 62.9 (BULLISH MOMENTUM)
SEC Form 4 / 13F Thermometer: 75% Net Buy • Cannibal Buyback (-2.08% YoY Shares)
Put hedging (50% put share) caps near-term gamma upside (-8 pts vs max)
Even with a 71/100 (B-) score, OPRX faces multiple-compression risk if 34.4x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Broader market pullbacks can still drag down strong stocks in the short run.
Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 64.8% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($8.27) or 200D SMA ($7.27) invalidates the momentum regime and cuts Target Base ($9.96) toward Bear Floor ($7.72).
OptimizeRx Corporation (OPRX) advanced +0.97% to $9.41, trading at 29% of its 52-week range ($4.54 – $21.09). High-quality cash engine (67.3% gross margin, 7% return on capital) with steady institutional support.
Yahoo Finance report covering OptimizeRx Corporation (OPRX) market action, institutional positioning, and fundamental catalysts.
StockInvest.us report covering OptimizeRx Corporation (OPRX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering OptimizeRx Corporation (OPRX) market action, institutional positioning, and fundamental catalysts.
www.marketscreener.com report covering OptimizeRx Corporation (OPRX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering OptimizeRx Corporation (OPRX) market action, institutional positioning, and fundamental catalysts.
Stock Traders Daily report covering OptimizeRx Corporation (OPRX) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering OptimizeRx Corporation (OPRX) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering OptimizeRx Corporation (OPRX) market action, institutional positioning, and fundamental catalysts.
WALTHAM, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare profess
Latest DSP integration expands buyer access to OptimizeRx point of care inventory through existing programmatic workflowsWALTHAM, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX),
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +18.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on OPRX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for OPRX. Explore sector supply chains on /butterfly.
Across 1009 tracked Consumer Discretionary securities in the Roarable RQD universe, OptimizeRx Corporation (OPRX) ranks #143 by composite RQD confidence (71/100, grade B-) and #703 by equity capitalization ($175.6M). Within this direct 5-issuer industry benchmark cohort, OPRX leads on earnings valuation at 34.4x trailing P/E, while OPRX leads on capital efficiency and profitability with 7.3% ROIC and 67.3% gross margin. OPRX currently leads its immediate peer cohort in composite quantitative strength at 71/100 (B-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| OPRX
ACTIVE
OptimizeRx Corporation | B- | 71/100 | 34.4x | 67.3% | 7.3% | +0.97% | $175.6M | Benchmark Subject |
| UXIN Uxin Limited ADS | E | 29/100 | — | 6.7% | -35.0% | +1.79% | $195.8M | /uxin-vs-oprx → |
| DHX DHI Group Inc. | D | 51/100 | — | 84.7% | -7.4% | +5.75% | $196.3M | /dhx-vs-oprx → |
| AMWL American Well Corporation (Class A) | D- | 39/100 | — | — | -35.0% | -1.65% | $216.5M | /amwl-vs-oprx → |
| CURR Currenc Group Inc. | E | 31/100 | — | 40.8% | -35.0% | -8.96% | $238.0M | /curr-vs-oprx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), OptimizeRx Corporation (OPRX) reported GAAP revenue of $109.4M (+18.8% vs. FY2024 revenue of $92.1M , and +53.0% cumulative change since FY2023) , GAAP net income of $5.1M, operating cash flow of $18.7M, and free cash flow of $18.7M (+290.6% YoY). On the balance sheet, OPRX closed FY2025 with $176.9M in total assets against $21.4M in total debt (Altman Z-Score: 2.68, Piotroski F-Score: 9/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $109.4M | $5.1M | $18.7M | $18.7M | $176.9M | $21.4M |
| FY2024 (FY) | 2024-12-31 | $92.1M | -$20.1M | $4.9M | $4.8M | $171.2M | $30.8M |
| FY2023 (FY) | 2023-12-31 | $71.5M | -$17.6M | -$7.2M | -$7.2M | — | — |
As of 2026-11-03, OptimizeRx Corporation (NASDAQ: OPRX) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 71/100 at a spot price of $9.41 (+0.97% 1D, market cap $175.6M). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 12/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 16/20, and Executive Insider Alignment 15/20. Across 1009 tracked Consumer Discretionary issuers, OPRX ranks #143 in composite RQD confidence.
Within the Consumer Discretionary sector (Business Services), OPRX carries a Roarable B- (71/100 RQD), trailing P/E of 34.4x, gross margin of 67.3%, and ROIC of 7.3%. By comparison, UXIN (Uxin Limited ADS) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $195.8M) and DHX (DHI Group Inc.) posts a D grade (51/100 RQD, P/E N/A, ROIC -7.4%, cap $196.3M). Among the 5-stock peer group, OPRX leads on earnings multiple (34.4x) while OPRX leads on capital efficiency (7.3% ROIC).
Per OPRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001448431), OptimizeRx Corporation generated $109.4M in revenue (+18.8% YoY), $5.1M in net income, and $18.7M in free cash flow against $176.9M in total assets and $21.4M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.
OPRX last traded at $9.41 (+0.97% on volume of 148,290 shares), positioning the stock +13.78% above its 50-day simple moving average ($8.27) and +29.44% above its 200-day simple moving average ($7.27). Across its 52-week range of $4.54 to $21.09, OPRX sits at the 29.4% percentile with a 14-day RSI of 62.9 (BULLISH MOMENTUM) and an implied next-earnings move of ±9.9% ($8.48 to $10.34).
OptimizeRx Corporation (OPRX) earns a live Roarable RQD composite score of 71/100, corresponding to a B- letter grade (Roarable Buy) at a spot price of $9.41 (+0.97% 1D, market capitalization $175.6M).
Sector is Consumer Discretionary and industry is Business Services, listed on NASDAQ. The profile section does not describe the company's products, customers, or revenue model. Gross margin is 67.3%, operating margin is 10.7%, and net margin is 4.7%.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), OptimizeRx Corporation (OPRX) reported $109.4M in annual revenue (up from $92.1M in FY2024, +18.8% YoY) and $5.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($71.5M revenue, -$17.6M net income) through FY2025, OPRX scaled operating cash flow to $18.7M and free cash flow to $18.7M, backed by $176.9M in total assets against $21.4M in total debt.
Operating in Business Services (Consumer Discretionary), OPRX carries a macro regime beta of 1.00 and gross margin of 67.3%.
Real-time company headlines, analyst actions, and sector developments for OptimizeRx Corporation (OPRX) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering OptimizeRx Corporation (OPRX) market action, institutional positioning, and fundamental catalysts.
StockInvest.us report covering OptimizeRx Corporation (OPRX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering OptimizeRx Corporation (OPRX) market action, institutional positioning, and fundamental catalysts.
www.marketscreener.com report covering OptimizeRx Corporation (OPRX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering OptimizeRx Corporation (OPRX) market action, institutional positioning, and fundamental catalysts.
Stock Traders Daily report covering OptimizeRx Corporation (OPRX) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering OptimizeRx Corporation (OPRX) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering OptimizeRx Corporation (OPRX) market action, institutional positioning, and fundamental catalysts.
Don't sleep on OPRX's setup in Consumer Discretionary. Revenue rose from $71.5M in FY 2023 to $109.4M in FY 2025 while operating income turned positive at $11.7M, supported by a 10.57% FCF yield and a Piotroski F-Score of 9/9.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (71/100) backs up the fundamental quality.
@MeanReversion_88 Shorting a 12/20 institutional whale-flow stock at $9.32 is dangerous when funds are rotating into Consumer Discretionary.
Sitting on the sidelines or leaning short OPRX above $9.32. The stock trades at a P/E (TTM) of 34.4 and EV/EBITDA of 14.9 on EPS (TTM) of 0.27, with an Altman Z-Score of 2.68 and ROIC of only 7.3%.. Until Fundamental Cash Engine (14/20) and FCF yield (10.57%) inflect higher, upside is capped near $21.09.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: